PROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says

MT Newswires Live12-09

PROCEPT BioRobotics (PRCT) still has a large market opportunity for its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed, BofA Securities said in a Monday research report.

The company could achieve operating profitability in 2029, given it records a 20% revenue compound annual growth rate and gross margin of 60%, analysts wrote.

BofA's survey of urologists indicated moderate incremental market share capture for aquablation in BPH treatment, with maximum penetration expected at 23%. Limiting factors included prostate size, financial considerations, bleeding risks, and other treatments, according to the report.

The survey suggests aquablation procedure growth of 26% in 2026, 19% in 2027, and 18% in 2028. However, the brokerage stated that there are limitations to this analysis, as the survey may not represent the overall market.

The brokerage said it downgraded the stock to neutral from buy and lowered its price target to $38 per share from $55.

Price: 34.21, Change: -1.65, Percent Change: -4.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590035228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 00:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590035228","market":"fut","top_or_hot":-1,"title":"PROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PRCT\">PROCEPT BioRobotics</a> (PRCT) still has a large market opportunity for its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed, BofA Securities said in a Monday research report.</p><p>The company could achieve operating profitability in 2029, given it records a 20% revenue compound annual growth rate and gross margin of 60%, analysts wrote.</p><p>BofA's survey of urologists indicated moderate incremental market share capture for aquablation in BPH treatment, with maximum penetration expected at 23%. Limiting factors included prostate size, financial considerations, bleeding risks, and other treatments, according to the report.</p><p>The survey suggests aquablation procedure growth of 26% in 2026, 19% in 2027, and 18% in 2028. However, the brokerage stated that there are limitations to this analysis, as the survey may not represent the overall market.</p><p>The brokerage said it downgraded the stock to neutral from buy and lowered its price target to $38 per share from $55.</p><p>Price: 34.21, Change: -1.65, Percent Change: -4.60</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 00:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PRCT\">PROCEPT BioRobotics</a> (PRCT) still has a large market opportunity for its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed, BofA Securities said in a Monday research report.</p><p>The company could achieve operating profitability in 2029, given it records a 20% revenue compound annual growth rate and gross margin of 60%, analysts wrote.</p><p>BofA's survey of urologists indicated moderate incremental market share capture for aquablation in BPH treatment, with maximum penetration expected at 23%. Limiting factors included prostate size, financial considerations, bleeding risks, and other treatments, according to the report.</p><p>The survey suggests aquablation procedure growth of 26% in 2026, 19% in 2027, and 18% in 2028. However, the brokerage stated that there are limitations to this analysis, as the survey may not represent the overall market.</p><p>The brokerage said it downgraded the stock to neutral from buy and lowered its price target to $38 per share from $55.</p><p>Price: 34.21, Change: -1.65, Percent Change: -4.60</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2324357040.USD","symbol_name":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590035228","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590035228","pubTimestamp":1765211876,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PROCEPT BioRobotics  still has a large market opportunity for its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed, BofA Securities said in a Monday research report.The company could achieve operating profitability in 2029, given it records a 20% revenue compound annual growth rate and gross margin of 60%, analysts wrote.BofA's survey of urologists indicated moderate incremental market share capture for aquablation in BPH treatment, with maximum penetration expected at 23%. Limiting factors included prostate size, financial considerations, bleeding risks, and other treatments, according to the report.The survey suggests aquablation procedure growth of 26% in 2026, 19% in 2027, and 18% in 2028. However, the brokerage stated that there are limitations to this analysis, as the survey may not represent the overall market.The brokerage said it downgraded the stock to neutral from buy and lowered its price target to $38 per share from $55.Price:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","PRCT":"PROCEPT BioRobotics","BK4082":"医疗保健设备"},"translate_title":"美国银行表示，PROCEPT BioRobotics拥有巨大的市场机会，但利用率增长已放缓","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1.5},"content_text":"PROCEPT BioRobotics (PRCT) still has a large market opportunity for its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed, BofA Securities said in a Monday research report.The company could achieve operating profitability in 2029, given it records a 20% revenue compound annual growth rate and gross margin of 60%, analysts wrote.BofA's survey of urologists indicated moderate incremental market share capture for aquablation in BPH treatment, with maximum penetration expected at 23%. Limiting factors included prostate size, financial considerations, bleeding risks, and other treatments, according to the report.The survey suggests aquablation procedure growth of 26% in 2026, 19% in 2027, and 18% in 2028. However, the brokerage stated that there are limitations to this analysis, as the survey may not represent the overall market.The brokerage said it downgraded the stock to neutral from buy and lowered its price target to $38 per share from $55.Price: 34.21, Change: -1.65, Percent Change: -4.60","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590035228","isCrawlerRequest":true}